



# In vivo Antibodies Functional-Grade



Immune Checkpoint | Cell Depletion | Cancer Immunology

## Ultra Low Endotoxin In vivo mAbs

Extremely low endotoxin levels ( $\leq 0.5$  EU/mg -  $\leq 1$  EU/mg) for in vivo mouse studies or sensitive in vitro experiments

## Validated

Immune checkpoint blockade, neutralization, stimulation, cell depletion, ELISA, FC, ICC, IHC, IP, WB, CODEX®, CyTOF®

## Highly Pure

No preservatives, stabilizers, carrier proteins & made using sterilized PBS without K<sup>+</sup> and Ca<sup>2+</sup>.

## Super Consistent

cGMP-grade & extensively quality controlled with minimal protein A leaching and low aggregation ensuring excellent Lot-to-Lot reproducibility


Product Name	5mg Pack Sizes			25mg Pack Sizes			50mg Pack Sizes		
	Code			Code			Code		
Anti-Mouse PD-1 [29F.1A12] In Vivo mAb - Low Endotoxin	IVMB0031-5			IVMB0031-25			IVMB0031-50		
Anti-Human CD3 [UCHT-1] In Vivo mAb - Low Endotoxin	IVMB0117-5			IVMB0117-25			IVMB0117-50		
Anti-Mouse CD4 [GK1.5] In Vivo mAb - Low Endotoxin	IVMB0060-5			IVMB0060-25			IVMB0060-50		
Anti-Mouse CD8b.2 In Vivo mAb - Low Endotoxin	IVMB0093-5			IVMB0093-25			IVMB0093-50		
Anti-Mouse CD8a (Ly2) In Vivo mAb - Low Endotoxin	IVMB0068-5			IVMB0068-25			IVMB0068-50		
Mouse IgG1 Isotype Control [HKSP] - Low Endotoxin	IVMB0184-5			IVMB0184-25			IVMB0184-50		
Mouse IgG2a Isotype Control - Low Endotoxin	IVMB0188-5			IVMB0188-25			IVMB0188-50		
Rat IgG2b Isotype Control - Low Endotoxin	IVMB0200-5			IVMB0200-25			IVMB0200-50		
Rat IgG2a Isotype Control - Low Endotoxin	IVMB0199-5			IVMB0199-25			IVMB0199-50		

# SUPERIOR EFFICACY & QUALITY


## Antibodies and isotypes tested

Independent comparison of the in vivo efficacy and tolerability of clones of mAbs anti-PD-1 [RMP1-14 and 29F.1A12], and isotype controls versus Vendor B using a CT26 syngeneic model (murine colorectal carcinoma derived from BALB/c mice). All antibodies had matching isotype controls, and phosphate-buffered saline (PBS) was used as a control.

### ANTI-PD-1



Treatment	Tumor size Day 26 (mm <sup>3</sup> )	TGI Day 26 (%)	P-value
Isotype	1197 ± 697	-	-
RMP1-14	470 ± 597	61	0.049
29F.1A12	395 ± 432	67	0.018



Treatment	Tumor size Day 26 (mm <sup>3</sup> )	TGI Day 26 (%)	P-value
Isotype	1234 ± 670	-	-
RMP1-14	656 ± 704	47	0.114
29F.1A12	805 ± 939	35	0.312

Anti-PD-1 antibody clones (RMP1-14 and 29F.1A12) were more efficacious than Vendor B (Figure 1).

## Highly Pure with Low Endotoxin Levels

Specifications	<i>in vivo</i> mAbs Low Endotoxin	<i>in vivo</i> mAbs Ultra Low Endotoxin
Binding validation determined by WB, FC or ELISA	Yes	Yes
Endotoxin level determined by the LAL method	≤ 1.0 EU/mg	≤ 0.5 EU/mg
Antibody aggregation screening by analytical SEC	≥ 95% monomer	≥ 98% monomer
Purity by SDS PAGE	≥ 95%	≥ 98%
Formulation for <i>in vivo</i> use	No Preservatives No stabilizers No carrier protein Sterile PBS pH 7.2 - No K <sup>+</sup> or CA <sup>2+</sup> Concentration: > 5mg/mL	No Preservatives No stabilizers No carrier protein Sterile PBS pH 7.2 - No K <sup>+</sup> or CA <sup>2+</sup> Concentration: > 5mg/mL
Murine pathogen screening	Not applicable, see Ultra Low Endotoxin functional grade antibodies	Pathogen tested (IMPACT1) (see table)